Heart Messaging
Heart Messaging
Common Objections
100

AlloMap processing is a huge burden – my staff doesn’t want me to use AlloMap.

  • Dedicated CareDx care team can meet with lab director/clinical team to review AlloMap processing logistics and offer support (CVA pg 13/14)
  • Pivot back to importance of AlloMap: risk stratification (CVA pg 10); prognosis of future graft injury/early detection of risk before Allosure result is positive (CVA pg 11)
  • AlloMap provides critical clinical insights not available if using AlloSure alone
100

AlloMap processing is a huge burden – my staff doesn’t want me to use AlloMap.

  • What is the burden your team is experiencing?
  • Dedicated CareDx care team can meet with lab director/clinical team to review AlloMap processing logistics and offer support (CVA pg 13/14)
  • Pivot back to importance of AlloMap: risk stratification (CVA pg 10); prognosis of future graft injury/early detection of risk before Allosure result is positive (CVA pg 11)
  • AlloMap provides critical clinical insights not available if using AlloSure alone

100

I don't want to use AlloSure due to the cost. 

clarify, 95% patients do not incur an OOP. Robust financial assistance program

200

I’m not sure what to do with discordant results.

  • HeartCare is the only test that provides a Personalized Risk Report, combining measures of immune activation & graft injury for more precise risk assessment (CVA pg 4/5)
  • Reference the frequency of discordant results in SHORE (CVA pg 5)
  • When HeartCare results are discordant they offer clinical insights that may be missed when relying solely on dd-cfDNA - review clinical results interpretation (CVA pg 5)
200

I’m not sure what to do with discordant results

  • HeartCare is the only test that provides a Personalized Risk Report, combining measures of immune activation & graft injury for more precise risk assessment (CVA pg 4/5)
  • Reference the frequency of discordant results in SHORE (CVA pg 5)
  • When HeartCare results are discordant they offer clinical insights that may be missed when relying solely on dd-cfDNA - review clinical results interpretation (CVA pg 5)
200

I am going to stick with Prospera Kidney because it is integrated into my EMR. 

Clarify - question - 

300

I still find biopsy to be the gold standard. I want to continue to use it as my surveillance method for my post-transplant patients.

  • Biopsy has long been the gold standard in transplant surveillance. But recent SHORE data shows that in certain low-risk patients, routine biopsies may not add clinical value, and could even expose patients to uneccesary risk (CVA pg 8/10/12)
  • Patients with AlloMap+ and AlloSure+ had doubled risk of poor outcomes (even in absence of histological rejection) when compared to patients with AlloMap- and AlloSure- (CVA pg 8)
  • No correlation between the rate of redundant surveillance biopsies and patient survival/outcomes (CVA pg 12)
  • HeartCare doesn’t replace biopsy – but can help you decide when a biopsy is truly necessary; reserve for when HeartCare suggests elevated risk
300

I still find biopsy to be the gold standard. I want to continue to use it as my surveillance method for my post-transplant patients

  • How many surveillance biopsies does your protocol recommend in the first year post-transplant?
  • Biopsy has long been the gold standard in transplant surveillance. But recent SHORE data shows that in certain low-risk patients, routine biopsies may not add clinical value, and could even expose patients to uneccesary risk (CVA pg 8/10/12)
  • Patients with AlloMap+ and AlloSure+ had doubled risk of poor outcomes (even in absence of histological rejection) when compared to patients with AlloMap- and AlloSure- (CVA pg 8)
  • No correlation between the rate of redundant surveillance biopsies and patient survival/outcomes (CVA pg 12)
  • HeartCare doesn’t replace biopsy – but can help you decide when a biopsy is truly necessary; reserve for when HeartCare suggests elevated risk
300

I am struggling to gain consensus among my nephrologists to utilize AlloSure

What is the impact on outcomes if staff does not practice consistently... 

400

I’m glad to know there is long-term prognostic value of HeartCare, but what about help with making short-term clinical decisions?

  • Patients with a single dual positive AlloMap+ and AlloSure+ between 2 months and 5 years post-transplant are 3x more likely to experience poor short-term outcomes (within 30 days)  (CVA pg 9)
400

I’m glad to know there is long-term prognostic value of HeartCare, but what about help with making short-term clinical decisions?

Patients with a single dual positive AlloMap+ and AlloSure+ between 2 months and 5 years post-transplant are 3x more likely to experience poor short-term outcomes (within 30 days)  (CVA pg 9)

400

I like DSQ for my Heart Transplant patients. I am happy with Natera

DDC 

M
e
n
u